Login / Signup

An international survey on aminoglycoside practices in critically ill patients: the AMINO III study.

Claire RogerBenjamin LouartLoubna ElotmaniGreg BartonLeslie EscobarDespoina KoulentiJeffrey LipmanMarc LeoneLaurent MullerCaroline BoutinJulien AmourIouri BanakhJoel CoussonJeremy BourenneJean-Michel ConstantinJacques AlbaneseJason A RobertsJean-Yves Lefrantnull null
Published in: Annals of intensive care (2021)
Short courses of high AG doses are mainly used in ICU patients with septic shock, although wide variability in AG usage is reported. We could show no correlation between PK/PD target attainment and clinical outcome. Efforts to optimize the first AG dose remain necessary. Trial registration Clinical Trials, NCT02850029, registered on 29th July 2016, retrospectively registered, https://www.clinicaltrials.gov.
Keyphrases
  • septic shock
  • clinical trial
  • quantum dots
  • highly efficient
  • phase ii
  • visible light
  • primary care
  • phase iii
  • healthcare
  • intensive care unit
  • study protocol
  • pseudomonas aeruginosa
  • quality improvement
  • cystic fibrosis